Dofequidar

A quinoline derivative and inhibitor of multidrug resistance

此产品仅用于科学研究，我们不为任何个人用途提供产品和服务

库存: 现货

可选规格

包装

价格

促销价

数量
5mg

￥1075.00

860.00

- +
10mg

￥1687.00

1350.00

- +
50mg

￥5512.00

4410.00

- +
100mg

￥8525.00

6820.00

- +

已选 0 种 0 瓶

金额: ￥0.00

首页收藏

货号: ajce56026
CAS: 129716-58-1
别名: 1-[4-[2-羟基-3-(5-喹啉基氧基)丙基]-1-哌嗪基]-2,2-二苯基乙酮
分子式: C30H31N3O3
分子量: 481.59
纯度: >98%
溶解度: Soluble in DMSO
储存: Store at -20°C
库存: 现货

Background

Dofequidar is a quinoline derivative and inhibitor of multidrug resistance.^1,2 It inhibits P-glycoprotein in a photolabeling assay when used at a concentration of 100 μM.¹ Dofequidar (10 μM) increases intracellular accumulation of [³H]-vincristine in HL-60R cells endogenously expressing the gene encoding multidrug resistance-associated protein (MRP).² It restores susceptibility to vincristine- or doxorubicin-induced cytotoxicity in vincristine-resistant P388, vincristine-resistant K562, and doxorubicin-resistant K562 cells in a concentration-dependent manner.¹ Dofequidar (80 mg/kg twice per day) increases survival in a vincristine-resistant P388 murine leukemia model compared with untreated controls when administered in combination with vincristine .

1.Sato, W., Fukazawa, N., Nakanishi, O., et al.Reversal of multidrug resistance by a novel quinoline derivative, MS-209Cancer Chemother. Pharmacol.35(4)271-277(1995) 2.Narasaki, F., Oka, M., Fukuda, M., et al.A novel quinoline derivative, MS-209, overcomes drug resistance of human lung cancer cells expressing the multidrug resistance-associated protein (MRP) geneCancer Chemother. Pharmacol.40(5)425-432(1997)